A PET Study With RO5545965 in Healthy Male Volunteers
NCT01923025 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9
Last updated 2016-11-02
Summary
This single center, open-label study will evaluate the PK-PDE10A Enzyme Occupancy Relationship of RO5545965 after a single dose in healthy male volunteers by positron emission tomography (PET).
Conditions
Interventions
- DRUG
-
RO5545965
Single dose
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Study Design
- Allocation
- NA
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 25 Years
- Max Age
- 50 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2013-08-31
- Primary Completion
- 2013-11-30
- Completion
- 2013-11-30
Countries
- United Kingdom
Study Locations
More Related Trials
-
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981 ·Status: COMPLETED
-
Studies of Frontal Lobe Brain Functioning in Schizophrenia
NCT00001258 ·Status: COMPLETED
-
Oculomotor and Spatial Cognition Deficits in Schizophrenia
NCT00931996 ·Status: TERMINATED ·Phase: NA
-
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
NCT00570063 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males
NCT02935725 ·Status: COMPLETED ·Phase: PHASE1
-
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
NCT00364429 ·Status: TERMINATED ·Phase: PHASE1
-
Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia
NCT03911726 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Psychosis-Associated Neuroinflammation in Schizophrenia
NCT02009826 ·Status: COMPLETED
-
Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242
NCT02824666 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia
NCT05462340 ·Status: TERMINATED ·Phase: PHASE1
-
Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers
NCT04588129 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia
NCT01555697 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly
NCT03809325 ·Status: COMPLETED
-
The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders
NCT03166098 ·Status: COMPLETED
-
A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder
NCT01116830 ·Status: COMPLETED ·Phase: PHASE1
-
Early Clinical Evaluation of the Pharmacokinetics and Mechanism Based Pharmacodynamics of Haloperidol Using Positron Emission Tomography in Healthy Volunteers
NCT01193621 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia
NCT02202226 ·Status: COMPLETED ·Phase: PHASE1
-
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
NCT04787302 ·Status: COMPLETED ·Phase: PHASE1
-
An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia
NCT01634542 ·Status: COMPLETED
-
5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
NCT02435654 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacologic Treatment in Legal Offenders With Schizophrenia, a Prospective Observational Mirror Image Study.
NCT05939765 ·Status: WITHDRAWN
-
A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients
NCT00725855 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers
NCT01749098 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
NCT01095562 ·Status: COMPLETED ·Phase: PHASE2
-
Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia
NCT02001103 ·Status: UNKNOWN ·Phase: PHASE3